Skip to content

Transcranial Direct Current Stimulation of the Primary Motor Cortex to Treat Levodopa-induced Dyskinesias

Transcranial Direct Current Stimulation of the Primary Motor Cortex to Treat Levodopa-induced Dyskinesias in Patients With Parkinson's Disease.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05752240
Enrollment
32
Registered
2023-03-02
Start date
2022-03-10
Completion date
2025-03-10
Last updated
2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

The main objective of the study is to evaluate the efficacy of 10 sessions of transcranial direct current stimulation of the primary motor cortex to reduce levodopa-induced dyskinesia

Interventions

DEVICETranscranial direct current stimulation

Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients with diagnosis of idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria and levodopa-induced dyskinesia; * age between 30 and 80 years; * ongoing therapy with levodopa; * fulfillment of requirements for the application of transcranial magnetic stimulation (TMS), assessed by completion of the TMS screening questionnaire.

Exclusion criteria

* patients unable to give informed consent; * cognitive impairment (MMSE ≤ 24); * history of epilepsy; * pregnant women.

Design outcomes

Primary

MeasureTime frameDescription
Reduction of dyskinesia15 daysChange in the total score of part III of the Unified Dyskinesia Rating Scale (range 0-112, 112 is the worse outcome) in on motor state at the assessment made three days after the end of treatment compared with the assessment made at baseline in the groups of patients treated with tDCS and sham-stimulation, respectively

Countries

Italy

Contacts

Primary ContactFrancesco Bove, MD
francesco.bove@policlinicogemelli.it+390630156433

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026